X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STERLING BIOTECH AJANTA PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 20.0 -1.8 - View Chart
P/BV x 8.6 0.1 12,443.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AJANTA PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
STERLING BIOTECH
Dec-13
AJANTA PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,72011 16,381.0%   
Low Rs1,1033 32,441.2%   
Sales per share (Unadj.) Rs194.626.8 726.0%  
Earnings per share (Unadj.) Rs45.2-15.0 -302.3%  
Cash flow per share (Unadj.) Rs50.3-5.5 -920.7%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.054.9 240.6%  
Shares outstanding (eoy) m88.77267.87 33.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.3 2,797.6%   
Avg P/E ratio x31.2-0.5 -6,717.6%  
P/CF ratio (eoy) x28.1-1.3 -2,205.9%  
Price / Book Value ratio x10.70.1 8,441.9%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,862 6,730.4%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m2,570547 470.0%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m17,2757,181 240.6%  
Other income Rs m16643 390.4%   
Total revenues Rs m17,4427,223 241.5%   
Gross profit Rs m5,807947 613.3%  
Depreciation Rs m4512,543 17.7%   
Interest Rs m494,377 1.1%   
Profit before tax Rs m5,474-5,931 -92.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460-1,924 -75.9%   
Profit after tax Rs m4,014-4,007 -100.2%  
Gross profit margin %33.613.2 254.9%  
Effective tax rate %26.732.4 82.2%   
Net profit margin %23.2-55.8 -41.6%  
BALANCE SHEET DATA
Current assets Rs m7,63914,335 53.3%   
Current liabilities Rs m2,71549,809 5.5%   
Net working cap to sales %28.5-494.0 -5.8%  
Current ratio x2.80.3 977.7%  
Inventory Days Days43403 10.7%  
Debtors Days Days79171 46.1%  
Net fixed assets Rs m6,91455,432 12.5%   
Share capital Rs m177268 66.0%   
"Free" reserves Rs m11,44213,935 82.1%   
Net worth Rs m11,72114,701 79.7%   
Long term debt Rs m1499,478 1.6%   
Total assets Rs m14,81473,988 20.0%  
Interest coverage x112.9-0.4 -31,818.3%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x1.20.1 1,201.5%   
Return on assets %27.40.5 5,475.5%  
Return on equity %34.2-27.3 -125.7%  
Return on capital %46.5-6.4 -724.1%  
Exports to sales %55.125.9 212.9%   
Imports to sales %6.00.2 3,535.2%   
Exports (fob) Rs m9,5271,860 512.3%   
Imports (cif) Rs m1,03812 8,504.9%   
Fx inflow Rs m10,4221,860 560.4%   
Fx outflow Rs m1,67825 6,742.5%   
Net fx Rs m8,7441,835 476.5%   
CASH FLOW
From Operations Rs m3,2641,719 189.9%  
From Investments Rs m-2,093-3,148 66.5%  
From Financial Activity Rs m-1,1861,426 -83.1%  
Net Cashflow Rs m-15-3 435.3%  

Share Holding

Indian Promoters % 73.8 33.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 9.9 76.8%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.0 39.3 43.3%  
Shareholders   20,968 21,482 97.6%  
Pledged promoter(s) holding % 4.4 55.9 7.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - PLETHICO PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS